سعر هيرتراز 440 مجم فيال 2026

• Adults: HER2-overexpressing breast cancer (adjuvant treatment as part of specified chemotherapy regimens or as a single agent after anthracycline-based therapy, and metastatic breast cancer); select patients with an FDA-authorized companion diagnostic.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adults: HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in breast cancer: fever, nausea, vomiting, infusion reactions, diarrhoea, infections, increased cough, headache, fatigue, dyspnoea, rash, neutropenia, anaemia and myalgia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Metastatic gastric cancer (increased versus chemotherapy alone): neutropenia, diarrhoea, fatigue, anaemia, stomatitis, weight loss, upper respiratory infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis and dysgeusia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• None (US label).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - cardiomyopathy: can cause subclinical and clinical cardiac failure and decreased LVEF, with greatest risk when given with anthracyclines; evaluate cardiac function before and during treatment and discontinue for cardiomyopathy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning - infusion reactions and pulmonary toxicity: serious and fatal reactions can occur, usually during or within 24 hours of administration; interrupt for dyspnoea or significant hypotension and discontinue for anaphylaxis, angioedema, interstitial pneumonitis or ARDS.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning - embryo-fetal toxicity: exposure during pregnancy can cause oligohydramnios, sometimes with pulmonary hypoplasia and neonatal death; verify pregnancy status before starting and advise effective contraception during treatment and for 7 months after the last dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: use during pregnancy resulted in oligohydramnios and oligohydramnios sequence (pulmonary hypoplasia, skeletal abnormalities, neonatal death); report exposure during pregnancy or within 7 months of the last dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk or effects on the breastfed infant; human IgG is present in milk but not absorbed substantially; weigh breastfeeding benefits against maternal need, considering the 7-month washout period.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.